Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997

被引:117
作者
Murdych, T
Weisdorf, DJ
机构
[1] Univ Minnesota, Blood & Marrow Tranplant Program, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA
关键词
cardiac; marrow transplant; toxicity;
D O I
10.1038/sj.bmt.1703133
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Cardiac complications may result from high-dose chemotherapy or irradiation administered during the conditioning phase of bone marrow and blood stem cell transplantation (BMT). To assess the frequency of clinically serious cardiac toxicity related to the acute phase of BMT, we retrospectively examined life-threatening or fatal cardiotoxicity identified using the complications records of our transplant center clinical database. All serious cardiac toxicity events within 100 days of BMT except those attributable to septic shock, pneumonitis or multi-organ failure were reviewed. Of 2821 BMT patients at the University of Minnesota between 1977 and 1997, 26 were identified as having suffered major or fatal (n = 13) cardiotoxicity (0.9%, 19 adults and seven children). Rapidly progressive heart failure resulted in death of 11 patients, one patient had fatal pericardial tamponade, and one had an acute ventricular fibrillation arrest. The remaining 13 patients (50%) had life-threatening cardiotoxicity including four patients with pericardial tamponade and nine patients with cardiac arrhythmias. Overall, we observed that acute, major cardiotoxic events attributable to BMT are uncommon, occurring with a frequency of <1%. These data suggest that with appropriate pre-transplant clinical evaluation, high-dose cyclophosphamide and irradiation in the BMT preparative phase does not result in frequent, clinically relevant short-term cardiac toxicity.
引用
收藏
页码:283 / 287
页数:5
相关论文
共 20 条
[1]   IDARUBICIN CARDIOTOXICITY - A RETROSPECTIVE STUDY IN ACUTE MYELOID-LEUKEMIA AND MYELODYSPLASIA [J].
ANDERLINI, P ;
BENJAMIN, RS ;
WONG, FC ;
KANTARJIAN, HM ;
ANDREEFF, M ;
KORNBLAU, SM ;
OBRIEN, S ;
MACKAY, B ;
EWER, MS ;
PIERCE, SA ;
ESTEY, EH .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) :2827-2834
[2]  
APPELBAUM FR, 1987, CANCER TREAT REP, V71, P115
[3]  
BAELLO EB, 1986, CANCER TREAT REP, V70, P1187
[4]  
BEARMAN SI, 1990, BONE MARROW TRANSPL, V5, P173
[5]   CYCLOPHOSPHAMIDE CARDIOTOXICITY IN BONE-MARROW TRANSPLANTATION - A PROSPECTIVE EVALUATION OF NEW DOSING REGIMENS [J].
BRAVERMAN, AC ;
ANTIN, JH ;
PLAPPERT, MT ;
COOK, EF ;
LEE, RT .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) :1215-1223
[6]  
BUJA LM, 1976, HUM PATHOL, V7, P17
[7]  
CAZIN B, 1986, CANCER, V57, P2061, DOI 10.1002/1097-0142(19860515)57:10<2061::AID-CNCR2820571031>3.0.CO
[8]  
2-H
[9]  
CROSSLEY RJ, 1984, SEMIN ONCOL, V11, P54
[10]   CARDIAC TOXICITY OF BONE-MARROW TRANSPLANTATION - PREDICTIVE VALUE OF CARDIOLOGIC EVALUATION BEFORE TRANSPLANT [J].
HERTENSTEIN, B ;
STEFANIC, M ;
SCHMEISER, T ;
SCHOLZ, M ;
GOLLER, V ;
CLAUSEN, M ;
BUNJES, D ;
WIESNETH, M ;
NOVOTNY, J ;
KOCHS, M ;
ADAM, WE ;
HEIMPEL, H ;
ARNOLD, R .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (05) :998-1004